Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This is a two-part dose-finding trial of MK-7680 in participants with Hepatitis C Virus (HCV)
infection of genotype (GT)1 (Part I) and GT3 (Part 2). The primary hypothesis is that daily
administration of a safe and well tolerated dose of MK-7680 will produce a decrease in HCV
viral load.